Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed diagnosis of 1 of the following:

Multiple myeloma
Non-Hodgkin's lymphoma
Hodgkin's lymphoma
Relapsed or refractory disease

Measurable disease, as defined according to diagnosis as follows:

Multiple myeloma, meeting 1 of the following criteria:

Serum monoclonal protein ≥ 1.0 g/dL
Urine monoclonal protein ≥ 200 mg by 24-hour electrophoresis
Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)

Lymphoma, meeting 1 of the following criteria:

Measurable disease by CT scan or MRI or PET/CT scan, defined as ≥ 1 lesion that has a single diameter of ≥ 2 cm OR tumor cells in the blood ≥ 5 x10^9/L

Skin lesions can be used if the area is ≥ 2 cm in ≥ 1 diameter and photographed with a ruler

Lymphoplasmacytic lymphoma without measurable lymphadenopathy, meeting both of the following criteria:

Bone marrow lymphoplasmacytosis with > 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy
Quantitative IgM monoclonal protein > 1,000 mg/dL
Not a candidate for known standard potentially curative therapy

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Life expectancy ≥ 12 weeks
ANC ≥ 1,500/mm³
Hemoglobin ≥ 9 g/dL
Platelet count ≥ 75,000/mm³
Bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal
AST ≤ 3 times ULN (5 times ULN if liver involvement)
Creatinine ≤ 2.5 times ULN
INR < 1.5 or activated PTT < 1.5 times ULN (no concurrent anticoagulants)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception during and for at least 2 weeks after completion of study treatment
No uncontrolled infection
No NYHA class III-IV congestive heart failure
No unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months)
No myocardial infarction within the past 6 months
No uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg, despite optimal medical management
No known HIV positivity
No other active malignancy requiring treatment
No inability to swallow
No gastrointestinal (GI) function impairment or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, or small bowel resection) or preclude use of oral medications
No thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months
No pulmonary hemorrhage or bleeding event ≥ grade 3 within the past 4 weeks
No severe or uncontrolled medical conditions or other conditions that would preclude study compliance
No liver disease, such as cirrhosis, chronic hepatitis or chronic persistent hepatitis, or uncontrolled infections
No serious nonhealing wound, ulcer, or bone fracture
No evidence or history of serious bleeding diathesis or coagulopathy, such as hemophilia or von Willebrand's disease
No significant traumatic injury within the past 4 weeks
No known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus)

PRIOR CONCURRENT THERAPY:

More than 3 weeks since prior myelosuppressive chemotherapy or biological therapy and recovered

More than 4 weeks since prior major surgery or open biopsy

Lymph node biopsy within past 4 weeks allowed
Prior everolimus allowed

No concurrent immunosuppressant therapy

Concurrent stable chronic doses of steroids (≤ 20 mg of prednisone per day) for disorders other than lymphoma (i.e., rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, asthma) or for pruritus or fever associated with lymphoma allowed
Concurrent corticosteroids at the lowest possible dose necessary to control symptoms in patients with CNS lymphoma allowed
No concurrent CYP450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)
No other concurrent immunotherapy, radiotherapy, or chemotherapy
No concurrent chronic oxygen therapy
No concurrent warfarin or heparin
No other concurrent investigational therapy